ClinicalTrials.gg
Active, not recruitingNCT03049189COMPETEUpdated Oct 20, 2026Results posted

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

A Phase 3 interventional study of 177Lu-edotreotide PRRT and Everolimus in Neuroendocrine Tumors, sponsored by ITM Solucin GmbH. Active, not recruiting at 52 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by ITM Solucin GmbH · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Neuroendocrine Tumors with a site in Germany — 6 open to participants now, 10 under way, 4 of them phase 3. Neuroendocrine Tumors · Germany.

Enrollment
7th of 27
324 · median 160
Started
2017
with 3 others
Phase 3
7 of 36
none open now
Registered
22nd of 36
by date
Lead sponsor
2 of 36
ITM Solucin GmbH

Among the 36 studies in Neuroendocrine Tumors with a site in Germany, this one is the 7th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2017, is one of 7 in phase 3, and was the 22nd registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

6 of the 36 studies in Neuroendocrine Tumors with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Neuroendocrine Tumors with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

03

Conditions studied

  • Neuroendocrine Tumors

Browse trials for

Keywords

  • non-functional and functional P-NET
  • non-functional GE-NET
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of well-differentiated neuro-endocrine tumour of non-functional gastroenteric origin (GE-NET) or both functional or non-functional pancreatic origin (P-NET)
  • per 1.1
  • Somatostatin receptor positive (SSTR+) disease
  • Progressive disease based on RECIST 1.1. criteria as evidenced by two morphological imaging examinations made with the same imaging method (either CT or MRI)

Exclusion criteria

Exclusion Criteria:

  • Known to edotreotide or everolimus
  • Known hypersensitivity to DOTA, lutetium-177, or any of edotreotide or everolimus or any other Rapamycin derivative
  • Prior exposure to any peptide receptor radionuclide therapy (PRRT)
  • Prior therapy with mTor inhibitors
  • Prior EFR (external field radiation) to GEP-NET lesions within 90 days before randomisation or radioembolisation therapy
  • Therapy with an compound and/or medical device within 30 days prior to randomisation
  • Indication for surgical lesion removal with curative potential
  • Planned alternative therapy (for the period of study participation)
  • Serious non-malignant disease
  • renal, hepatic, cardiovascular, or haematological organ dysfunction, potentially interfering with the safety of the study treatments
  • Pregnant or breast-feeding women
  • Subjects not able to declare meaningful on their own (e.g. with legal guardian for mental disorders) or any other vulnerable population to that sense (e.g. persons institutionalised, incarcerated etc.).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    177Lu-edotreotide PRRT

    177Lu-edotreotide (177Lu-DOTATOC) A maximum of four cycles of 7.5 ± 0.7 GBq (gigabequerel) 177Lu-edotreotide, each. Route of administration: Slow intravenous infusion/injection (i.v.) Duration of treatment: 4 cycles, 90 days apart (total duration: 270 days/9 months)

    Drug: 177Lu-edotreotide PRRT · Other: Amino-Acid Solution

  • Active comparator
    Everolimus

    Everolimus (Afinitor ®) Doses: 10 mg/d Route of administration: Oral Duration of treatment: Continuous daily treatment until diagnosis of progression or End of Study (EOS)

    Drug: Everolimus

Interventions

  • Drug177Lu-octreotide, DOTA(0)-Tyr(3)-Studies of 177Lu-octreotide, DOTA(0)-Tyr(3)-177Lu-octreotide, DOTA(0)-Tyr(3)- pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.

    Also known as: 177Lu-DOTATOC, 177Lu-Edo

  • Everolimus will be administered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.

    Also known as: Afinitor

  • OtherAmino-Acid Solution

    The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT

    Also known as: Arginine-Lysine Solution

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS determined as time elapsed between randomization, and the date of first objective report of tumor progression (evaluated by RECIST criteria v1.1) as evaluated by the Blinded Independent Central Review (BICR), or death.

    Time frame: From date of randomization until the date of first documented progression or death, assessed up to 30 months,

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR will be assessed, defined as the proportion of participants achieving partial response (PR) or complete response (CR) as best outcome, after treatment with 177Lu-edotreotide compared to everolimus.

    Time frame: Up to 30 months

  2. Overall Survival (OS)

    From the date of randomisation until the date of death up to the up to the end of the 5 year post-study follow-up.

    Time frame: Overall Survival (OS) will be followed up for 5 years (60 months) after the End of Study (EOS)

07

Results

Posted Apr 6, 2026
Limitations and caveats
\[Not Specified\]

Participant flow

The study was conducted in 14 countries. Of the 52 sites that screened at least one participant, 49 sites randomized at least one participant. A total of 324 participants were enrolled in the study. Of these, 309 (95.4%) were randomized in a 2:1 fashion to the 177Lu-edotreotide arm or the control arm. Of the 309 randomized participants, 7 did not receive treatment.

Participant flow — Overall Study
Milestone177Lu-edotreotide PRRTEverolimusNon-Randomized Participants of Sub-Study C
Started2039914
Safety analysis set (saf)2039914
Full analysis set (fas)2071020
Completed63184
Not completed1408110
Withdrew: Progressive disease107539
Withdrew: Adverse event17130
Withdrew: Protocol violation320
Withdrew: Non-compliance120
Withdrew: Pregnancy010
Withdrew: Death750
Withdrew: Other (including withdrawal by subject, sponsor request, technical problems)550
Withdrew: Other: ongoing001

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS determined as time elapsed between randomization, and the date of first objective report of tumor progression (evaluated by RECIST criteria v1.1) as evaluated by the Blinded Independent Central Review (BICR), or death.

Time frame:
From date of randomization until the date of first documented progression or death, assessed up to 30 months,
Reported as:
Median · Months
Progression-Free Survival (PFS)
Months177Lu-edotreotide PRRTEverolimus
Progression-Free Survival (PFS)23.9 (18.7 to 30.0)14.1 (9.2 to 20.9)
Statistical analysis
  • 177Lu-edotreotide PRRT vs Everolimus · Log Rank · p = 0.0223 (\[Not Specified\]) · Hazard ratio (hr): 0.673 · 95% CI 0.477 to 0.948Hazard ratio is expressed as 177Lu-edotreotide/everolimus and estimated from the corresponding Cox model.
SecondaryObjective Response Rate (ORR)

ORR will be assessed, defined as the proportion of participants achieving partial response (PR) or complete response (CR) as best outcome, after treatment with 177Lu-edotreotide compared to everolimus.

Time frame:
Up to 30 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participants177Lu-edotreotide PRRTEverolimus
Objective Response Rate (ORR)21.9 (16.2 to 27.6)4.2 (0.2 to 8.2)
Statistical analysis
  • 177Lu-edotreotide PRRT vs Everolimus · Mantel Haenszel · p = <0.0001 (\[Not Specified\])Derived from a two-sided test between the investigational and control arm.
SecondaryOverall Survival (OS)

From the date of randomisation until the date of death up to the up to the end of the 5 year post-study follow-up.

Time frame:
Overall Survival (OS) will be followed up for 5 years (60 months) after the End of Study (EOS)

Results for this outcome have not been posted.

Adverse events

Collected over AEs are collected from the signature of the Informed Consent Form (ICF) until the End of Study (EOS), assessed up to approximately 30 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
177Lu-edotreotide PRRT14/217 (6.5%)66/217 (30.4%)204/217 (94%)
Everolimus7/99 (7.1%)44/99 (44.4%)98/99 (99%)
Most frequent serious events
Showing 10 of 134
Most frequent serious events
Event177Lu-edotreotide PRRTEverolimus
Acute kidney injuryRenal and urinary disorders1/2175/99
Intestinal obstructionGastrointestinal disorders2/2173/99
Diabetes mellitusMetabolism and nutrition disorders1/2173/99
CholecystitisHepatobiliary disorders5/2172/99
Tricuspid valve incompetenceCardiac disorders0/2172/99
Disease progressionGeneral disorders3/2172/99
PyrexiaGeneral disorders0/2172/99
COVID-19Infections and infestations2/2172/99
GastroenteritisInfections and infestations0/2172/99
PneumoniaInfections and infestations1/2172/99
Most frequent other events
Showing 10 of 66
Most frequent other events
Event177Lu-edotreotide PRRTEverolimus
DiarrhoeaGastrointestinal disorders78/21744/99
NauseaGastrointestinal disorders79/21721/99
AstheniaGeneral disorders65/21736/99
Mucosal inflammationGeneral disorders2/21729/99
Oedema peripheralGeneral disorders12/21729/99
AnaemiaBlood and lymphatic system disorders34/21727/99
StomatitisGastrointestinal disorders3/21725/99
FatigueGeneral disorders53/21717/99
HyperglycaemiaMetabolism and nutrition disorders12/21724/99
RashSkin and subcutaneous tissue disorders9/21724/99

Baseline characteristics

The baseline demographics are summarized for the Full Analysis Set (FAS), encompassing 309 participants, included all who were randomized to treatment and was used for all efficacy analyses.

Age, Continuous
Age, Continuous(Years)177Lu-edotreotide PRRTEverolimusTotal
Mean62.8 ± 11.659.7 ± 12.261.7 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)177Lu-edotreotide PRRTEverolimusTotal
Female9744141
Male11058168
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)177Lu-edotreotide PRRTEverolimusTotal
Black or African American448
White17784261
Multiple011
Not Reported261339
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)177Lu-edotreotide PRRTEverolimusTotal
Hispanic or Latino6915
Not Hispanic or Latino19389282
Unknown or Not Reported8412
Weight
Weight(Kg)177Lu-edotreotide PRRTEverolimusTotal
Mean73.70 ± 15.1474.13 ± 15.7273.84 ± 15.30
BMI (Body Mass Index)
BMI (Body Mass Index)(Kg/m2)177Lu-edotreotide PRRTEverolimusTotal
Mean25.59 ± 4.4825.32 ± 4.5025.51 ± 4.48
Height
Height(cm)177Lu-edotreotide PRRTEverolimusTotal
Mean169.47 ± 9.59170.80 ± 9.80169.89 ± 9.66
08

Study locations

52 sites
09

References and documents

Publications

  • Walter T, Jann H, Ansquer C, Deshayes E, Garcia-Carbonero R, Teule A, Baum RP, Verberne HJ, Cwikla JB, Srirajaskanthan R, de Mestier L, Grana CM, Buck A, Horsch D, Pavel M, Dierickx LO, Michael M, Strosberg J, Kollar A, Jimenez-Fonseca P, Rinke A, Del Olmo-Garcia M, Flaus A, Hernando J, Kluge A, Breuninger M, Melnyk S, Zhernosekov K, Capdevila J; COMPETE Investigator Team. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. Lancet. 2026 Jul 18;408(10551):234-247. doi: 10.1016/S0140-6736(26)00604-5. Epub 2026 Jul 2. PubMed 42392118 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Nov 2024, 93 months.

Results were first posted in Apr 2026, 1 year 4 months after primary completion.

Of 25 phase 3 interventional studies under Neuroendocrine Tumors, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 85. This study's 93 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2017
First posted
Feb 9, 2017
StartActual
Feb 2, 2017
Primary completionActual
Nov 27, 2024
CompletionEst.
Nov 2029
Results first posted
Apr 6, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03049189
Lead sponsor
ITM Solucin GmbH
Collaborators
ABX CRO, PSI CRO
Responsible party
Sponsor
First posted
Feb 9, 2017
Start date
Feb 2, 2017
Primary completion
Nov 27, 2024
Completion
Nov 2029 (estimated)
Results posted
Apr 6, 2026
Last update
Oct 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 177Lu-octreotide, DOTA(0)-Tyr(3)-

Start the discussion